US5733327A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Stent for liberating drug
Assignee: Individual
•
Filing: 1995-10-17
•
Granted: 1998-03-31
•
Expires: 2015-10-17
Abstract
Abstract A stent according to the present invention is adapted to be introduced into a vascular system such as blood vessels. The stent includes a stent body produced by weaving or knitting a fiber containing a drug and made of a low-melting biodegradable polymer into a tubular shape, or coating a drug-containing low-melting biodegradable polymer on a stent body. When the stent is introduced into the vascular system, the drug contained therein is dosed in a locally limited region of the vascular system. The low-melting biodegradable polymer used has a melting point of 80° C. or lower and is at least one compound selected from the group consisting of poly-ε-caprolactone, poly-D, L-deca-lactone, poly-dioxane and a copolymer thereof.
Inventors
- 👤 Keiji Igaki
- 👤 Hideo Tamai
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 14:56
CPC Classifications
A; A61; A61F; A61F2/00; A61F2/82; A61F2/86; A61F2/90; A61L; A61L31/00; A61L31/08; A61L31/10; A61L31/14; A61L31/16; A61F2210/00; A61F2210/0004; A61F2230/00; A61F2230/0002; A61F2230/0028; A61F2230/005; A61F2250/00; A61F2250/0058; A61F2250/0067; A61L2300/00; A61L2300/40; A61L2300/416; A61L2300/42
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
56 words
A stent for liberating TRANIRAST, which is adapted to be introduced into a vascular system such as blood vessels, comprising a stent body produced by weaving or knitting into a tubular shape a fiber containing TRANIRAST and made of a low-melting biodegradable polymer having a melting point at which no pharmacological effects of TRANIRAST are damaged.
Claim 2
Dependent Claim
56 words
A stent for liberating TRANIRAST, which is adapted to be introduced into a vascular system such as blood vessels, comprising a stent body produced by weaving or knitting into a tubular shape a fiber containing TRANIRAST and made of a low-melting biodegradable polymer having a melting point at which no pharmacological effects of TRANIRAST are damaged.
Claim 3
Dependent Claim
36 words
A stent for eluting TRANIRAST contained therein, comprising a stent body coated with a mixture composed of TRANIRAST and a low-melting biodegradable polymer having a melting point at which no pharmacological effects of TRANIRAST are damaged.
Claim 4
Dependent Claim
36 words
A stent for eluting TRANIRAST contained therein, comprising a stent body coated with a mixture composed of TRANIRAST and a low-melting biodegradable polymer having a melting point at which no pharmacological effects of TRANIRAST are damaged.
Claim 5
Dependent Claim
166 words
A stent for liberating a drug, which is adapted to be introduced into a vascular system such as blood vessels, comprising: a stent body produced by weaving or knitting into a tubular shape a composite fiber composed of fiber made of a low-melting biodegradable polymer having a melting point at which no pharmacological effects of the druq are damaged and a fiber made of a high-melting biodegradable polymer having a melting point higher than that of the fiber composed of the low-melting biodegradable polymer; wherein the low-melting biodegradable polymer exposed to an outer surface of the stent body is heat-fused to smoothen the outer surface; wherein the high-melting biodegradable polymer is at least compound selected from the group consisting of poly-lactic acid, polyglycolic acid and a copolymer thereof; wherein the melting point of the low-melting point biodegradable polymer is 80° C. or lower; and wherein the composite fiber constituting the stent body is a two folded yarn, the two folded yarn including a TRANIRAST-containing poly-ε-caprolactone fiber.
Claim 6
Dependent Claim
166 words
A stent for liberating a drug, which is adapted to be introduced into a vascular system such as blood vessels, comprising: a stent body produced by weaving or knitting into a tubular shape a composite fiber composed of fiber made of a low-melting biodegradable polymer having a melting point at which no pharmacological effects of the druq are damaged and a fiber made of a high-melting biodegradable polymer having a melting point higher than that of the fiber composed of the low-melting biodegradable polymer; wherein the low-melting biodegradable polymer exposed to an outer surface of the stent body is heat-fused to smoothen the outer surface; wherein the high-melting biodegradable polymer is at least compound selected from the group consisting of poly-lactic acid, polyglycolic acid and a copolymer thereof; wherein the melting point of the low-melting point biodegradable polymer is 80° C. or lower; and wherein the composite fiber constituting the stent body is a two folded yarn, the two folded yarn including a TRANIRAST-containing poly-ε-caprolactone fiber.
References Cited (Backward Citations)
US4548764A
Cited
US5044116A
Cited
US5019096A
Cited
US5545208A
Cited
US5464450A
Cited
US5423885A
Cited
EP0554082A1
Cited
JPH06221A
Cited
JPH067455A
Cited
EP0566245A1
Cited
US5366504A
Cited
JPH06218063A
Cited
EP0604022A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-03-30 | 2001-09-29 | 2002-03-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-03-30 | 2005-09-29 | 2006-03-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-03-30 | 2009-09-29 | 2010-03-31 | $7700.00 | Window Closed / Lapsed |